Search

Sandoz Group AG

Closed

36 -0.83

Overview

Share price change

24h

Current

Min

35.5

Max

36.22

Key metrics

By Trading Economics

Income

150M

Sales

5.1B

Dividend yield

1.62

Profit margin

2.963

Employees

22,049

EBITDA

541M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+17.51% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.62%

2.39%

Next Earnings

30 Apr 2025

Market Stats

By TradingEconomics

Market Cap

16B

Previous open

36.83

Previous close

36

Sandoz Group AG Chart

Past performance is not a reliable indicator of future results.

Related News

17 Dec 2024, 07:45 UTC

Market Talk

Sandoz's U.S. Settlement to Cost 1.1 Swiss Francs a Share -- Market Talk

17 Dec 2024, 07:34 UTC

Market Talk

Sandoz's U.S. Settlement Shows Commitment Move Forward -- Market Talk

10 Dec 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Sandoz Group AG Forecast

Price Target

By TipRanks

17.51% upside

12 Months Forecast

Average 43.524 CHF  17.51%

High 50 CHF

Low 38 CHF

Based on 8 Wall Street analysts offering 12 month price targets forSandoz Group AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

4

Buy

4

Hold

0

Sell

Financials

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.